Ausdal Financial Partners, Inc. Adaptimmune Therapeutics PLC Call Options Transaction History
Ausdal Financial Partners, Inc.
- $1.25 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADAP
# of Institutions
73Shares Held
113MCall Options Held
77.5KPut Options Held
14.2K-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$7.4 Million0.43% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR23.8MShares$6.41 Million0.16% of portfolio
-
Two Seas Capital LP Rye, NY20.5MShares$5.54 Million0.15% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$4.61 Million0.32% of portfolio
-
Mpm Asset Management LLC Cambridge, MA5.34MShares$1.44 Million1.54% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $44.1M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...